WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory
Novo NordiskNovo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,100 people in 79 countries and markets its products in more than 170 countries.

www.novonordisk.com

Filters
List of articles in category Novo Nordisk
Title Published Date
OzempicĀ® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors 05 March 2019
Abbott and Novo Nordisk enter partnership to provide integrated digital solution to people with diabetes using insulin 20 February 2019
Embark and Novo Nordisk enter collaboration to discover novel therapeutics for obesity and metabolic disease 08 November 2018
Addressing social and cultural drivers of type 2 diabetes is key to its treatment and prevention 02 October 2018
Novo Nordisk announces plans to transform its approach to Research & Development 19 September 2018
Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins 17 August 2018
Kallyope and Novo Nordisk announce collaboration to discover novel therapeutics for obesity and diabetes 19 June 2018
Novo Nordisk increases commitment to stem cell-based therapies 16 May 2018
Novo Nordisk participates in new research project Hypo-RESOLVE to investigate hypoglycaemia and its impact in diabetes 02 May 2018
Red Cross and Novo Nordisk announce ground-breaking partnership to tackle chronic care in humanitarian crises 19 April 2018
  • Start
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
  • End
Build the future of health through collaboration & innovation

Business & Industry

  • Abbott researchers find rare group of people with controlled HIV who could be a key to unlocking cure
  • Pfizer and BioNTech initiate a study as part of broad development plan to evaluate COVID-19 booster and new vaccine variants
  • Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate
  • Sanofi to provide manufacturing support to Johnson & Johnson for their COVID-19 vaccine to help address global supply demands
  • GSK and Vir Biotechnology expand coronavirus collaboration to advance new therapeutics for influenza and other respiratory viruses

Research & Development

  • Vaccine development software shows promise in influenza effort, could help defeat coronavirus
  • Researchers discover SARS-CoV-2 inhibitors
  • Nanoparticle-delivered COVID-19 vaccine candidate shows promise in preclinical studies
  • First COVID-19 COVAX vaccine doses administered in Africa
  • Assessing a compound's activity, not just its structure, could accelerate drug discovery
  • Arthritis drugs may reduce mortality and time in ICU for sickest COVID patients
  • Real-world effectiveness of COVID-19 vaccine

Conferences & Events

  • Scientists urge for investment now in highly potent vaccines to prevent the next pandemic
  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production

Regulatory Affairs

  • FDA issues Emergency Use Authorization for third COVID-19 vaccine
  • FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  1. You are here:  
  2. Home
  3. Novo Nordisk

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.